Effective July 1, 2018: Formulary Changes

On July 1, 2018, the formulary status of the following medications will change. WellDyneRx is committed to offering our clients and plan participants the best prescription benefit options at the lowest cost. To accomplish this, the clinical team at WellDyneRx partners with a Pharmacy and Therapeutics (P&T) committee to evaluate the efficacy and safety of new drug approvals and to review clinical components of existing medications.

These drugs were evaluated during the March 2018 P&T Committee meeting and final determinations were based upon multiple factors, including safety profile, therapeutic impact, medical necessity, and cost-effectiveness. Formularies play a critical role in prescription drug benefits as they guide medication therapy choices. The table below outlines the changes to the WellDyneRx Clinical Focus formulary.

The table below outlines the changes to the WellDyneRx Clinical Outcomes formulary.

We constantly evaluate our formulary to match patients with the most effective treatments. If there’s a better—or more practical—prescription option for our clients and members, we tell them. With that transparency comes trust. That’s the WellDyneRx approach.

2018 Quarter Two WellInformed Table Contents